Fluent

Fluent EV/EBITDA

Delisted

The EV/EBITDA (Enterprise Value to EBITDA) of Fluent (TIUM.U.CN) as of Nov 6, 2026 is 3.59. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 5.55 — a change of -35.20% (lower).

EV/EBITDA

3.59

YoY

-35.20%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Fluent is 2023 3.59 . EV/EBITDA (Enterprise Value to EBITDA) of Fluent was 2022 5.55 . It decreases by -35.20% lower compared to the previous year.

The Fluent EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
-2.51 USD
Jan 1, 2020
-4.68 USD
Jan 1, 2021
-9.89 USD
Jan 1, 2022
5.55 USD
Jan 1, 2023
3.59 USD
The Fluent EV/EBITDA history
YEAREV/EBITDAYoY
3.59-35.20%
5.55-156.10%
-9.89+111.16%
-4.68+86.30%
-2.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluent Stock analysis

What does Fluent do? Fluent Corp operates under the private label Fluent, selling medical cannabis products in Florida, Texas, and Pennsylvania. The company's products include oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges, edibles, and accessories. Subsidiaries such as Cansortium Holdings LLC and Cansortium Florida, LLC handle production and sales, while Fluent Servicing, LLC manages servicing aspects. The company's revenue comes from direct sales of medical cannabis products through its licensed operations in multiple states. Fluent Corp's target customers are patients seeking medical cannabis treatments, with products tailored to various consumption methods. The company leverages its subsidiaries to maintain compliance and expand its market reach across different states. Sales are conducted through licensed dispensaries and medical cannabis programs, focusing on the healthcare segment of the cannabis industry. The business model relies on the production and sale of medical cannabis under the private label Fluent, utilizing subsidiaries to manage state-specific operations. Products are distributed through established medical cannabis channels, with no mention of additional revenue streams beyond product sales. The company's focus remains on the medical cannabis market, serving patients in Florida, Texas, and Pennsylvania. Fluent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluent stock

EV/EBITDA (Enterprise Value to EBITDA) of Fluent is 3.59 in 2023.

EV/EBITDA (Enterprise Value to EBITDA) of Fluent changed from 5.55 to 3.59, representing a -35.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Fluent since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Fluent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Fluent

All Key Metrics — Fluent